Lv1
30 积分 2023-08-08 加入
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?
2天前
已完结
Continuation of same programmed death-1 inhibitor regime beyond progression is a novel option for advanced gastric cancer
16天前
已完结
Early Local Community Data on Safety and Efficacy of Fruquintinib in Metastatic Colorectal Cancer
16天前
已关闭
Le fruquintinib dans le cancer colorectal métastatique en échec des traitements standards
23天前
已关闭
EP.12D.07 Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series
30天前
已完结
EP.12D.07 Efficacy and Safety of Savolitinib for MET-Altered Non-Small Cell Lung Cancer (NSCLC) In First-Line Setting: A Case Series
30天前
已完结
EP.12A.38 Durable Response to Savolitinib in Advanced EGFR-WT NSCLC with MET Amplification: Case Series
30天前
已完结
Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study
1个月前
已完结
Fruquintinib-associated posterior reversible encephalopathy syndrome in a patient with multiply metastatic rectal cancer
1个月前
已完结
Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report
1个月前
已完结
皖公网安备34019202002308
